A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT03835819
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
  • IMGN853 — DRUG
    Mirvetuximab soravtansine is an antibody-drug conjugate.

Study Details

This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: * mirvetuximab soravtansine (IMGN853) * pembrolizumab

Key Dates

Start date
Jan 2, 2020
Status verified
May 2026
Primary completion
Jun 4, 2024
Completion
Feb 1, 2027

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: IMGN853 + Pembrolizumab
    * Pembrolizumab is administered intravenously once every 3 weeks * IMGN853 is administered intravenously once every 3 weeks

Primary Outcome Measure

Objective Response Rate [ Time Frame: 6 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02215-
University of MassachusettsWorcesterMassachusetts01605-
Northwell Cancer InstituteLake SuccessNew York11042-

Related coverage on Hipa.ai

Find similar trials in Boston, MA

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Dana Farber Cancer Institute· Boston, MAUniversity of Massachusetts· Worcester, MANorthwell Cancer Institute· Lake Success, NY

Related Studies